While President-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), a crucial spot for the biopharma industry remains open at the FDA.

The name on the top of the list for the next administration’s FDA commissioner is Johns Hopkins surgeon and author Martin Makary, Reuters and Bloomberg reported this week, citing sources familiar with the matter.

England-born Makary, current chief of Inlet Transplant Surgery at Johns Hopkins, has received worldwide recognition for his achievements in novel surgeries and widely-used research, including a World Health Organization-sponsored checklist on surgical safety.

On the drug policy front, Makary has previously raised concerns about pharmaceutical companies “gaming the system” of the Orphan Drug Act, a pathway used to usher in treatments for rare diseases.